Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLNN NASDAQ:COCP NASDAQ:CUE NASDAQ:DTIL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLNNClene$5.80-6.1%$4.47$2.28▼$7.10$58.17M0.58122,248 shs119,184 shsCOCPCocrystal Pharma$1.58+9.7%$1.60$1.12▼$3.26$16.21M2.2840,859 shs82.95 million shsCUECue Biopharma$0.74-3.2%$0.80$0.45▼$1.99$58.84M1.58114,041 shs362,116 shsDTILPrecision BioSciences$4.61-7.8%$4.80$3.61▼$10.68$58.94M1.6159,590 shs368,830 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLNNClene-6.15%-3.81%+58.90%+41.46%-4.76%COCPCocrystal Pharma+9.72%+7.12%-5.95%+2.60%-3.07%CUECue Biopharma-3.16%-4.94%-8.49%+23.17%+25.81%DTILPrecision BioSciences-7.80%-9.07%-1.71%-5.92%-56.10%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLNNClene$5.80-6.1%$4.47$2.28▼$7.10$58.17M0.58122,248 shs119,184 shsCOCPCocrystal Pharma$1.58+9.7%$1.60$1.12▼$3.26$16.21M2.2840,859 shs82.95 million shsCUECue Biopharma$0.74-3.2%$0.80$0.45▼$1.99$58.84M1.58114,041 shs362,116 shsDTILPrecision BioSciences$4.61-7.8%$4.80$3.61▼$10.68$58.94M1.6159,590 shs368,830 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLNNClene-6.15%-3.81%+58.90%+41.46%-4.76%COCPCocrystal Pharma+9.72%+7.12%-5.95%+2.60%-3.07%CUECue Biopharma-3.16%-4.94%-8.49%+23.17%+25.81%DTILPrecision BioSciences-7.80%-9.07%-1.71%-5.92%-56.10%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLNNClene 3.00Buy$32.60462.07% UpsideCOCPCocrystal Pharma 3.00Buy$6.00279.75% UpsideCUECue Biopharma 0.00N/AN/AN/ADTILPrecision BioSciences 3.00Buy$47.00919.52% UpsideCurrent Analyst Ratings BreakdownLatest COCP, CLNN, CUE, and DTIL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025CLNNCleneBenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$33.00 ➝ $31.008/21/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.008/18/2025CLNNCleneCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$83.00 ➝ $48.008/14/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.007/18/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.006/30/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.006/20/2025COCPCocrystal PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$7.00 ➝ $6.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLNNClene$286K203.41N/AN/A($1.06) per share-5.47COCPCocrystal PharmaN/AN/AN/AN/A$0.94 per shareN/ACUECue Biopharma$8.29M6.88N/AN/A$0.28 per share2.65DTILPrecision BioSciences$1.26M43.09N/AN/A$6.87 per share0.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLNNClene-$39.40M-$3.76N/AN/AN/A-10,386.36%N/A-125.49%11/12/2025 (Estimated)COCPCocrystal Pharma-$17.50M-$1.24N/AN/AN/AN/A-144.12%-102.85%11/12/2025 (Estimated)CUECue Biopharma-$40.67M-$0.56N/AN/AN/A-469.35%-230.13%-111.16%11/13/2025 (Estimated)DTILPrecision BioSciences$7.17M-$8.81N/AN/AN/A-6,205.79%-176.47%-69.05%11/3/2025 (Estimated)Latest COCP, CLNN, CUE, and DTIL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CLNNClene-$0.49-$0.78-$0.29-$0.78$0.06 million$0.03 million8/14/2025Q2 2025COCPCocrystal Pharma-$0.30-$0.20+$0.10-$0.20N/AN/A8/12/2025Q2 2025CUECue Biopharma-$0.13-$0.09+$0.04-$0.09$2.00 million$2.95 million8/7/2025Q2 2025DTILPrecision BioSciences-$0.09-$2.13-$2.04-$2.13$6.27 million$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLNNCleneN/AN/AN/AN/AN/ACOCPCocrystal PharmaN/AN/AN/AN/AN/ACUECue BiopharmaN/AN/AN/AN/AN/ADTILPrecision BioSciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLNNCleneN/A1.581.57COCPCocrystal PharmaN/A3.693.69CUECue Biopharma0.011.601.60DTILPrecision BioSciences0.665.185.18Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLNNClene23.28%COCPCocrystal Pharma6.72%CUECue Biopharma35.04%DTILPrecision BioSciences37.99%Insider OwnershipCompanyInsider OwnershipCLNNClene35.30%COCPCocrystal Pharma28.14%CUECue Biopharma10.78%DTILPrecision BioSciences4.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLNNClene10010.03 million6.49 millionOptionableCOCPCocrystal Pharma1010.26 million7.37 millionNot OptionableCUECue Biopharma6076.85 million68.56 millionOptionableDTILPrecision BioSciences20011.79 million11.26 millionNo DataCOCP, CLNN, CUE, and DTIL HeadlinesRecent News About These CompaniesPrecision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure SymposiumSeptember 12 at 7:01 AM | businesswire.comPrecision BioSciences announces in vivo gene editing program patent from USPTOSeptember 8, 2025 | msn.comPrecision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program StatusSeptember 8, 2025 | businesswire.comQ3 EPS Estimate for Precision BioSciences Boosted by AnalystAugust 16, 2025 | marketbeat.comPrecision BioSciences Reports Promising Phase 1 Trial ResultsAugust 14, 2025 | theglobeandmail.comPrecision BioSciences Reports Significant Quarterly LossAugust 12, 2025 | theglobeandmail.comDTIL Revenue Drops 99%August 7, 2025 | fool.comPrecision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue EstimatesAugust 7, 2025 | zacks.comPrecision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 7, 2025 | businesswire.comPrecision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis BAugust 6, 2025 | businesswire.comPrecision BioSciences to Report Second Quarter 2025 Results on August 7, 2025August 4, 2025 | businesswire.comPrecision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular DystrophyJuly 23, 2025 | businesswire.comTag: PrecisionJuly 20, 2025 | opi.netOSona BLW Precision Forgings shares rise 2.07% in morning tradeJuly 18, 2025 | moneycontrol.comSona BLW Precision Forgings share price falls 2.31%; stock among top losers on Nifty Midcap 150July 18, 2025 | moneycontrol.comPrecision Reloading Expands with Nosler, Bullets, Brass, and Ammunition to Elevate Shooting ExperienceJuly 18, 2025 | usatoday.comPrecision Drilling Gets a Lift: Piper Sandler Sees 40% UpsideJuly 18, 2025 | msn.comSona BLW Precision shares jump 9%; here's what triggered the upmoveJuly 17, 2025 | msn.comPrecision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards ClinicJuly 16, 2025 | businesswire.comDixon Technologies Joins Forces with Chongqing Yuhai for Precision Manufacturing in IndiaJuly 16, 2025 | devdiscourse.comDKaman Measuring Highlights Family of Precision Measuring Systems for Free Space Optical CommunicationJuly 9, 2025 | automation.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeCOCP, CLNN, CUE, and DTIL Company DescriptionsClene NASDAQ:CLNN$5.80 -0.38 (-6.15%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$5.93 +0.13 (+2.24%) As of 09/12/2025 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.Cocrystal Pharma NASDAQ:COCP$1.58 +0.14 (+9.72%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.47 -0.11 (-6.96%) As of 09/12/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.Cue Biopharma NASDAQ:CUE$0.74 -0.02 (-3.16%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.75 +0.01 (+1.69%) As of 09/12/2025 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.Precision BioSciences NASDAQ:DTIL$4.61 -0.39 (-7.80%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$4.64 +0.03 (+0.65%) As of 09/12/2025 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
